SCHEMBL23218595

SCHEMBL23218595

CCOC(=O)Cc1ccc(OC)cc1OCc1c(C)oc2ccc(-c3ccnc(CN)c3F)cc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 3/20 0.39
TSHR P16473 2/20 0.39
KDM4E B2RXH2 5/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
LMNA P02545 1/20 0.35
MAPK1 P28482 1/20 0.35
HTT P42858 1/20 0.35
MEN1 O00255 1/20 0.34
KMT2A Q03164 1/20 0.34
GAA P10253 4/20 0.34
PTGS2 P35354 1/20 0.34
ALDH1A1 P00352 4/20 0.33
HPGD P15428 3/20 0.33
MAPT P10636 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ANO1 Q5XXA6 1/20 0.33
POLB P06746 1/20 0.33
PDE10A Q9Y233 1/20 0.33
GLA P06280 1/20 0.33
PTPN1 P18031 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852482 1.00 DPP4 (0.39) DPP4TSHRKDM4EL3MBTL1LMNA
SCHEMBL23218613 0.92 CD274 (0.39) KDM4EGAASMN1; SMN2ANO1POLB
SCHEMBL29591350 0.92 CD274 (0.39) KDM4EGAASMN1; SMN2ANO1POLB
SCHEMBL29852953 0.89 TSHR (0.40) DPP4TSHRKDM4EL3MBTL1LMNA
SCHEMBL23218205 0.89 TSHR (0.40) DPP4TSHRKDM4EL3MBTL1LMNA
SCHEMBL23218394 0.88 TSHR (0.38) TSHRKDM4EL3MBTL1LMNAMAPK1
SCHEMBL23218399 0.86 TSHR (0.41) DPP4TSHRKDM4EL3MBTL1LMNA
SCHEMBL29852645 0.86 TSHR (0.41) DPP4TSHRKDM4EL3MBTL1LMNA
SCHEMBL23218232 0.83 TSHR (0.40) DPP4TSHRKDM4EL3MBTL1MEN1
SCHEMBL23218876 0.83 TSHR (0.40) DPP4TSHRKDM4ELMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB DPP4 1386/4885TSHR 1199/4885KDM4E 4172/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB DPP4 1004/4885TSHR 3148/4885KDM4E 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.